CathVision, a medical technology company developing electrophysiology solutions designed to enhance clinical decision-making, announced the US Food and Drug Administration clearance and commercial availability of the PVI Analyzer and Signal Complexity algorithms.
These algorithms are part of the Cardialytics suite of artificial intelligence (AI)-powered analytics integrated into the ECGenius System.
The ECGenius System is now the only electrophysiology recording system with an AI algorithm to facilitate electrogram interpretation and deliver intelligent, automated analyses designed to help physicians improve ablation outcomes in complex atrial arrhythmia procedures by measuring the success of cardiac ablation.
The Cardialytics suite includes:
- PVI Analyzer: a signal-based AI algorithm capable of confirming pulmonary vein isolation status across multiple cardiac ablation modalities when physicians treat complex arrhythmias such as atrial fibrillation.
- Signal Complexity: an algorithm to help physicians visualize and quantify atrial fibrillation complexity parameters in patients with persistent atrial fibrillation.
These tools are available to physicians using the ECGenius System on a price-per-use basis.
“CathVision’s technology has taken us back to our roots in cardiac electrophysiology and improved upon critical data that was vastly overlooked for many years,” says Larry Chinitz, MD, family professor of medicine and cardiac electrophysiology and director of cardiac electrophysiology and Heart Rhythm Center at NYU Langone, in a release. “With improved signal quality providing accurate and meaningful data, the integration of Cardialytics’ uniquely principled AI tools will continue CathVision’s transformation of electrophysiology.”
ECGenius System is CathVision’s electrophysiology recording technology and proprietary hardware amplifier that acquires high-fidelity, low-noise cardiac electrograms to help electrophysiologists improve the diagnosis and treatment of complex atrial arrhythmias, including atrial fibrillation.
Unlike traditional electrophysiology recording systems that often capture electrogram signals marred by noise and artifact, ECGenius delivers a necessary evolution in the quality of intracardiac and electrocardiogram signal acquisition, the accuracy of electrogram interpretation, and the advancement of therapy support, according to a release from the company. With data from the ECGenius System, intelligent automated analyses can effectively enable physicians to confirm the success of ablation efforts.
“Our mission has always been to put electrophysiologists in the best position to improve clinical outcomes. Incorporating AI-based analytics into the ECGenius System is another important demonstration of our unique ability to deliver on that mission and achieve groundbreaking milestones. With clinical enhancements exclusively available in our ECGenius System, we maintain our leadership position in equipping electrophysiologists with the technology necessary to elevate patient outcomes,” says Mads Matthiesen, CEO of CathVision, in a release. “CathVision is poised for an exciting phase as we launch the ECGenius System with Cardialytics and intensify our research endeavors to continue delivering innovative technology that simplifies processes.”
Photo caption: ECGenius System
Photo credit: CathVision